AB-1001 Gene Therapy for huntington disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 Sep 2022: Trial registered, NCT05541627
  2. 12 Oct 2022: Trial started, NCT05541627

The trials

NCT05541627: A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease

State
Under way
Phase
Phase 1 and Phase 2
People
5 taking part
Started
12 Oct 2022
Primary completion
4 Apr 2024
Arms
Cohort 1, Cohort 2
Results
None posted
  1. 15 Sep 2022: Trial registered
  2. 12 Oct 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Gene therapy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.